Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China

Abstract

Application of auto-SCT in the post-remission therapy for adolescents and young adults (AYAs) with ALL is controversial. We analyzed the outcomes of 79 AYAs (15–24 years) with ALL who received our designed total therapy protocol with auto-SCT in first CR from 1990 to 2009. The estimated OS and EFS at 5 years for the cohort were 62.8±5.9 and 61.5±5.7%. The cumulative non-relapse mortality and relapse rate at 5 years for the cohort were 7.2±3.1 and 33.6±5.8%. Time to CR >4 weeks was the only independent unfavorable factor associated with OS, EFS and relapse in multivariate analysis. Patients in standard risk (SR) group and high risk (HR) group had better OS (78.3±7.4, 63.8±10.2 vs 38.1±11.6%) and EFS (78.0±7.4, 63.4±9.4 vs 32.4±11.3%), and lower relapse rate (15.9±6.5, 31.5±9.5 vs 65.7±11.8%) compared with patients in very high risk (VHR) group. Our data confirmed that auto-SCT-based total therapy might be an optional treatment strategy for AYAs with ALL in SR. Patients in HR also could get benefit from such schedule. But for those in VHR, allogenetic SCT is still the prior recommendation for the frequent recurrence after auto-SCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30.

    Article  PubMed  Google Scholar 

  2. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813–819.

    Article  CAS  PubMed  Google Scholar 

  3. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J et al. Allogenetic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12: 2580–2587.

    Article  CAS  PubMed  Google Scholar 

  4. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86: 1619–1628.

    CAS  PubMed  Google Scholar 

  5. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients 50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004; 89: 809–817.

    PubMed  Google Scholar 

  6. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104: 3028–3037.

    Article  CAS  PubMed  Google Scholar 

  7. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.

    Article  CAS  PubMed  Google Scholar 

  8. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90: 1346–1356.

    CAS  PubMed  Google Scholar 

  9. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

    Article  CAS  PubMed  Google Scholar 

  10. Cornelissen JJ, van der Holt B, Verhoef GE, van′t Veer MB, van Oers MH, Schouten HC et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113: 1375–1382.

    Article  CAS  PubMed  Google Scholar 

  11. Fière D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on therapy for adult acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 1990–2001.

    Article  PubMed  Google Scholar 

  12. Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 2006; 20: 336–344.

    Article  PubMed  Google Scholar 

  13. Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780.

    Article  PubMed  Google Scholar 

  14. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48: 254–261.

    Article  PubMed  Google Scholar 

  15. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children′s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646–1654.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. DeAngelo DJ, Dahlberg S, Silverman LB, Couban S, Amrein PC, Seftel MD et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007; 110: 587 (abstract).

    Article  Google Scholar 

  17. Rijneveld AW, van der Holt B, Daenen SMGJ, Biemond BJ, A van de Loosdrecht A, de Weerdt O et al. High dose intensive chemotherapy, as is standard in childhood leukemia, is feasible and efficacious in adult patients with acute lymphoblastic leukemia (ALL) up to the age of 40: results from the Dutch-Belgian HOVON-70 Study. Blood 2009; 114: 323 (abstract).

    Google Scholar 

  18. Blaise D, Gaspard MH, Stoppa AM, Michel G, Gastaut JA, Lepeu G et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1990; 5: 7–12.

    CAS  PubMed  Google Scholar 

  19. Carey PJ, Proctor SJ, Taylor P, Hamilton PJ . Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77: 1593–1598.

    CAS  PubMed  Google Scholar 

  20. Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010; 148: 80–89.

    Article  CAS  PubMed  Google Scholar 

  21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458.

    Article  CAS  PubMed  Google Scholar 

  22. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for Cancer Cytogenetics.In: Mittelman F (eds). Supplement to an International System for Human Cytogenetic Nomenclature. Karger: Basel, 1991 pp. 1–53.

  23. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  PubMed  Google Scholar 

  24. Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307–1325.

    Article  PubMed  Google Scholar 

  25. DeAngelo DJ . The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2005, 123–130.

    Article  Google Scholar 

  26. Ribera JM, Oriol A . Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009; 23: 1033–1042.

    Article  PubMed  Google Scholar 

  27. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV . Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196–199.

    CAS  PubMed  Google Scholar 

  28. Harrison CJ . Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 147–156.

    Article  PubMed  Google Scholar 

  29. Faderl S, O′Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116: 1165–1176.

    Article  CAS  PubMed  Google Scholar 

  30. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010; 115: 1394–1405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Usvasalo A, Elonen E, Saarinen-Pihkala UM, Räty R, Harila-Saari A, Koistinen P et al. Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data. Leuk Res 2010; 34: 1476–1482.

    Article  CAS  PubMed  Google Scholar 

  32. Kantarjian H, Thomas D, O′Brien S, Cortes J, Giles F, Jeha S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788–2801.

    Article  CAS  PubMed  Google Scholar 

  33. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T . Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51: 50–60.

    Article  PubMed  Google Scholar 

  34. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M et al. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant 2008; 42: 105–112.

    Article  CAS  PubMed  Google Scholar 

  35. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post-induction treatment: a report from the children′s oncology group. J Clin Oncol 2009; 27: 5189–5194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Key Clinical Project from the Health Ministry of China (2010–2012), the Key Projects in the National Science & Technology Pillar Program (grant no. 2008BAI61B01) and the National Public Health Research Foundation (grant no. 201002024).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to J-X Wang or L-G Qiu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, J., Zou, DH., Li, ZJ. et al. An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China. Bone Marrow Transplant 47, 1087–1094 (2012). https://doi.org/10.1038/bmt.2011.220

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.220

Keywords

This article is cited by

Search

Quick links